DK2747561T3 - Behandling af symptomer associeret med kvindelig gastroparese - Google Patents
Behandling af symptomer associeret med kvindelig gastroparese Download PDFInfo
- Publication number
- DK2747561T3 DK2747561T3 DK12825447.1T DK12825447T DK2747561T3 DK 2747561 T3 DK2747561 T3 DK 2747561T3 DK 12825447 T DK12825447 T DK 12825447T DK 2747561 T3 DK2747561 T3 DK 2747561T3
- Authority
- DK
- Denmark
- Prior art keywords
- metoclopramide
- gastroparesis
- treatment
- composition
- symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (9)
1. Formulering af metoclopramid til intranasal administration omfattende metoclopramid, citratbuffer og benzalkoniumchlorid, hvor formuleringen haren pH på mindst 5 og hvor sammensætningen omfatter 5 mg til 25 mg af metoclopramid per alikvot, til anvendelse i behandlingen af et eller flere symptomer associeret med diabetisk gastroparese hos kvinder, og er til administration til diabetiske kvinder i en daglig dosis på 3-8 intranasale alikvoter.
2. Sammensætningen til anvendelse ifølge et hvilket som helst af krav 1, hvor sammensætningen af metoclopramid er til administration med en daglig dosis på 20 mg til 100 mg metoclopramidbase per dag.
3. Sammensætningen til anvendelse ifølge et hvilket som helst af krav 2, hvor sammensætningen af metoclopramid er til administration med en daglig dosis på 40 mg til 80 mg metoclopramidbase per dag.
4. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor den daglige dosis af sammensætningen af metoclopramid er til administration som alikvoter med en volumen på 25 pL til 150 pL.
5. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor metoclopramidet, eller farmaceutisk acceptabelt salt deraf, administreres i en 50 mikroliter alikvot, fire gange per dag.
6. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor metoclopramidet, eller farmaceutisk acceptabelt salt deraf, administreres i en 70 mikroliter alikvot, fire gange per dag.
7. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor det ene eller flere symptomer af diabetisk gastroparese hos kvinder inkluderer et eller flere symptomer valgt fra gruppen bestående af kvalme, kløgning, opkastning, fyldt mave, appetitløshed, oppustethed, øvre underlivssmerter, og øvre underlivsgener.
8. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-7, til behandling af to eller flere symptomer af diabetisk gastroparese hos kvinder.
9. Sammensætningen til anvendelse ifølge kravene 1-8, hvor de to eller flere symptomer af diabetisk gastroparese hos kvinder inkluderer øvre underlivssmerter, øvre underlivsgener, opkastning og kvalme.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527563P | 2011-08-25 | 2011-08-25 | |
| US201261583447P | 2012-01-05 | 2012-01-05 | |
| PCT/US2012/052096 WO2013028882A1 (en) | 2011-08-25 | 2012-08-23 | Treatment of symptoms associated with female gastroparesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2747561T3 true DK2747561T3 (da) | 2018-08-06 |
Family
ID=47746868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12825447.1T DK2747561T3 (da) | 2011-08-25 | 2012-08-23 | Behandling af symptomer associeret med kvindelig gastroparese |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130217775A1 (da) |
| EP (1) | EP2747561B1 (da) |
| JP (3) | JP2014524478A (da) |
| CN (1) | CN103957707A (da) |
| BR (1) | BR112014004418A8 (da) |
| CA (1) | CA2846340A1 (da) |
| DK (1) | DK2747561T3 (da) |
| ES (1) | ES2683042T3 (da) |
| MX (1) | MX356317B (da) |
| PL (1) | PL2747561T3 (da) |
| PT (1) | PT2747561T (da) |
| RU (1) | RU2616520C2 (da) |
| TR (1) | TR201811221T4 (da) |
| WO (1) | WO2013028882A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| US11517545B2 (en) | 2016-12-15 | 2022-12-06 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
| WO2018191584A1 (en) * | 2017-04-14 | 2018-10-18 | The Johns Hopkins University | Nutritional and therapeutic supplement compositions |
| IL272023B1 (en) * | 2017-07-31 | 2024-08-01 | Theravance Biopharma R& D Ip Llc | Methods for treating the symptoms of gastric dysfunction using Velostrag |
| US20200276139A1 (en) * | 2017-09-11 | 2020-09-03 | Evoke Pharma, Inc. | Methods of intranasal metoclopramide dosing |
| CN113354553B (zh) * | 2021-06-03 | 2023-09-15 | 北京宝诺康医药科技有限公司 | 一种甲氧氯普胺单盐酸盐一水合物的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL281394A (da) | 1961-07-25 | |||
| US4624965A (en) | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
| US5760086A (en) | 1996-03-14 | 1998-06-02 | Ribogene, Inc. | Nasal administration of agents for treatment of delayed onset emesis |
| HUP9902891A3 (en) * | 1997-03-13 | 2000-11-28 | Ribogene Inc Hayward | Intranasal administration of a metoclopramide containing spray for treatment of delayed onset emesis |
| US6187332B1 (en) * | 1999-06-14 | 2001-02-13 | Wisconsin Alumni Research Foundation | Acidic buffered nasal spray |
| GB9918559D0 (en) * | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
| US6770262B2 (en) * | 2000-03-30 | 2004-08-03 | Questcor Pharmaceuticals, Inc. | Nasal administration of agents for the treatment of gastroparesis |
| US20030044356A1 (en) * | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
| US20050137265A1 (en) * | 2003-03-31 | 2005-06-23 | Haley Eugene T. | Rapidly dissolving metoclopramide solid oral dosage and method thereof |
| US20050175679A1 (en) * | 2004-02-10 | 2005-08-11 | Michael Moshman | Controlled release formulations |
| PL2376075T3 (pl) | 2008-12-22 | 2015-08-31 | Evoke Pharma Inc | Donosowe preparaty z metoklopramidu |
| EP2410999A4 (en) * | 2009-03-23 | 2012-04-18 | Laila Pharmaceuticals Pvt Ltd | CURCUMINOIDS AND THEIR METABOLIC PRODUCTS FOR ALLERGIC EYE / NOSIS DISEASES |
-
2012
- 2012-08-23 CN CN201280052214.2A patent/CN103957707A/zh active Pending
- 2012-08-23 TR TR2018/11221T patent/TR201811221T4/tr unknown
- 2012-08-23 PT PT128254471T patent/PT2747561T/pt unknown
- 2012-08-23 JP JP2014527302A patent/JP2014524478A/ja active Pending
- 2012-08-23 DK DK12825447.1T patent/DK2747561T3/da active
- 2012-08-23 BR BR112014004418A patent/BR112014004418A8/pt not_active Application Discontinuation
- 2012-08-23 RU RU2014111070A patent/RU2616520C2/ru active
- 2012-08-23 PL PL12825447T patent/PL2747561T3/pl unknown
- 2012-08-23 US US13/593,215 patent/US20130217775A1/en not_active Abandoned
- 2012-08-23 MX MX2014002125A patent/MX356317B/es active IP Right Grant
- 2012-08-23 EP EP12825447.1A patent/EP2747561B1/en active Active
- 2012-08-23 WO PCT/US2012/052096 patent/WO2013028882A1/en active Application Filing
- 2012-08-23 ES ES12825447.1T patent/ES2683042T3/es active Active
- 2012-08-23 CA CA2846340A patent/CA2846340A1/en active Pending
-
2017
- 2017-07-27 JP JP2017145855A patent/JP6511492B2/ja active Active
-
2018
- 2018-10-29 JP JP2018203340A patent/JP2019031551A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013028882A1 (en) | 2013-02-28 |
| RU2616520C2 (ru) | 2017-04-17 |
| ES2683042T3 (es) | 2018-09-24 |
| EP2747561A1 (en) | 2014-07-02 |
| CA2846340A1 (en) | 2013-02-28 |
| BR112014004418A8 (pt) | 2018-01-23 |
| JP6511492B2 (ja) | 2019-05-15 |
| PL2747561T3 (pl) | 2018-11-30 |
| MX2014002125A (es) | 2014-10-17 |
| PT2747561T (pt) | 2018-09-28 |
| US20130217775A1 (en) | 2013-08-22 |
| JP2014524478A (ja) | 2014-09-22 |
| TR201811221T4 (tr) | 2018-08-27 |
| CN103957707A (zh) | 2014-07-30 |
| RU2014111070A (ru) | 2015-09-27 |
| MX356317B (es) | 2018-05-23 |
| JP2019031551A (ja) | 2019-02-28 |
| EP2747561B1 (en) | 2018-05-09 |
| EP2747561A4 (en) | 2014-12-24 |
| JP2018008979A (ja) | 2018-01-18 |
| BR112014004418A2 (pt) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220151960A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP6511492B2 (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| US11033543B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
| US20230094778A1 (en) | Treatment of moderate and severe gastroparesis | |
| CA2893836C (en) | A combination medicament comprising phenylephrine and paracetamol | |
| US20170087104A1 (en) | Medicament | |
| US10046052B2 (en) | Method and formulation for cold treatment in adults and children with increased safety | |
| US20040192781A1 (en) | Method of administration for metoclopramide and pharmaceutical formulation therefor | |
| RU2788450C2 (ru) | Способы проведения терапии потери веса у пациентов с доминирующей депрессией |